Navigation Links
Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
Date:6/25/2009

effect -- can be a real breakthrough in CF patients' arduous treatment burden , and are looking forward to seeing the Phase II results and moving to Phase III soon afterward," said Tim Whitten, Transave's President and Chief Executive Officer. "We are grateful for the continued support of the CF Foundation as we strive to improve treatment options for CF patients."

The double-blind, 3 cohort, placebo-controlled study is designed to evaluate ARIKACE in the treatment of CF patients with Pseudomonas lung infections. A total of 46 patients have been randomized. ARIKACE or placebo are administered once daily for 28 days using an eFlow(R) Nebulizer System (PARI Pharma GmbH), a novel, highly efficient, portable aerosol delivery system. Eighteen clinical sites throughout the United States are participating in the study.

About ARIKACE(TM)

ARIKACE is a sustained-release formulation of the antibiotic amikacin, which encloses the drug in nanocapsules of lipid called liposomes. This advanced pulmonary liposome technology prolongs the release of amikacin in the lungs while minimizing systemic exposure. The treatment uses biocompatible lipids endogenous to the lung that are formulated into small (0.3 micron), neutral liposomes that enable penetration of the biofilm and are highly efficient, with a very low lipid-to-drug ratio (0.65). ARIKACE can be delivered through nebulization, which enables the small aerosol droplet size (1 to 5 microns) to facilitate more effective distribution in the lungs.

Positive Phase II results were announced in June 2008 from a clinical trial in European CF patients with Pseudomonas lung infections. The company also previously announced completion of enrollment in another Phase II trial in which ARIKACE is being evaluated in the treatment of non-CF patients who have bronchiectasis with Pseudomonas lung infections. In the
'/>"/>

SOURCE Transave, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... HILL, N.C. , Jan. 23, 2015 For the ... are in dealing with payers. Likewise, the importance of the ... - will only continue to grow as payer formularies and ... access therapies. At the same time, managed markets ...
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ... "Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends ... Video communication has been the topic of fascination ... the United States and the Soviet Russia. Earlier ...
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ... the "Urinary Catheters Market (Indwelling or Foley Catheters, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... , At present, the global market for ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
... Data Show Bifeprunox Maintained Stability,Significantly Longer than ... Profile Comparable with Placebo , MARIETTA, Ga. ... Solvay,Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of ... results on,bifeprunox, an investigational treatment for adult ...
... 2007 /PRNewswire-FirstCall/ -- Forest,Laboratories, Inc. and Cypress ... from a 1,196 patient randomized,three month, double-blind, ... therapeutic effects of,milnacipran as a treatment of ... only been able to review initial top-line,results ...
Cached Medicine Technology:New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 6
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the ... created for kids with cancer. The Chemo Duck App, available on ... with enjoyable games to help children of all ages living with ... to keep kids entertained, educated and at ease while waiting for ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... CAMBRIDGE, Mass., Oct 2 Biopure Corporation,(Nasdaq: BPUR ... became,effective at 12:01 a.m. October 2, 2007, with post-split ... today. The outstanding,warrants, including those trading on the OTCBB ... reduced and the exercise prices,increased by the 1-for-5 ratio. ...
... Positioned as Growth Platform, NEW YORK, and ... New-York-based private investment firm, announced today that,it has ... national,marketer of personal protective equipment, safety equipment, first ... America Corporation.,The transaction has a value of approximately ...
... Efforts for Pulmonary Study, SOLANA BEACH, ... LLC, a firm specializing in patient recruitment ... team of Regional Recruitment,Specialists(TM) in support of ... Obstructive Pulmonary Disease (COPD) for a recently ...
... YORK, Oct. 2, 2007 - When it comes to preventing ... Perhaps most surprising, women are more afraid of getting ... times more deaths per year. , These are among the ... of Texas M. D. Anderson Cancer Center and Prevention of ...
... Corey Goodman Steps Down; John Walker, Board Chair, Named Executive ... ... 1 Renovis,Inc. (Nasdaq: RNVS ), a biopharmaceutical company focused on ... of,neurological and inflammatory diseases, today announced that Corey Goodman,Ph.D., will step down ...
... cough ... suppressant, CHESTER, ... today announced that the Food and Drug,Administration (FDA) approved its supplemental ... Friday,Sept. 28, 2007. The Company will immediately commence distribution of grape,Delsym ...
Cached Medicine News:Health News:Biopure Announces Reverse Stock Split 2Health News:Biopure Announces Reverse Stock Split 3Health News:Caxton-Iseman Capital Acquires Conney Safety Products, LLC 2Health News:RESolutions Rapid Enrollment Solutions, LLC Mobilizes Team of Regional Recruitment Specialists(TM) 2Health News:M. D. Anderson-Prevention poll finds women can do more to prevent cancer...but aren't 2Health News:M. D. Anderson-Prevention poll finds women can do more to prevent cancer...but aren't 3Health News:Renovis Announces Management Changes 2Health News:Renovis Announces Management Changes 3Health News:Renovis Announces Management Changes 4Health News:Renovis Announces Management Changes 5
... blood oximeters provide cardiologists with critical ... a patient's blood. The Oxicom series ... over a half-million saturation samples measured ... cost-effective oxygen saturation readings in less ...
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
Medicine Products: